Roxithromycin Atid Dosage

How times a day do you take this medicine?

Dosage of Roxithromycin Atid in details

infoThe dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.

Adults: Recommended Dose: Mild to Moderate Acute Bacterial Exacerbations of COPD, Pneumonia of Mild Severity, Pharyngitis, Tonsillitis and Uncomplicated Skin and Skin Structure Infections: 500 mg as a single dose on the 1st day followed by 250 mg once daily on days 2 through 5.

Genital Ulcer Disease: 1000 mg as single dose.

Urethritis and Cervicitis: 2000 mg as single dose. Capsule should be given at least 1 hr before or 2 hrs after a meal. Azithromycin tablets can be taken with or without food.

Children: Use of azithromycin in children <6 months is not recommended.

What other drugs will affect Roxithromycin Atid?

It is not likely that other drugs you take orally or inject will have an effect on topically applied erythromycin. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Roxithromycin Atid interactions

infoInteractions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Roxithromycin Atid, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.

Roxithromycin Atid has a much lower affinity for cytochrome P450 than

erythromycin, and consequently has fewer interactions. Interactions may be

observed, however, with drugs that bind to alpha-1-acid glycoprotein, e.g.


Roxithromycin Atid does not appear to interact with oral contraceptives,

prednisolone, carbamazepine, ranitidine or antacids.

Theophylline. A study in normal subjects concurrently administered

Roxithromycin Atid and theophylline has shown some increase in the plasma

concentration of the latter. While a change in dosage is usually not required,

patients with high levels of theophylline at commencement of treatment

should have levels monitored.

Ergot alkaloids. Reactions of ergotism with possible peripheral necrosis have

been reported after concomitant therapy of macrolides with vasoconstrictive ergot alkaloids, particularly ergotamine and dihydroergotamine. Because a

clinical interaction with Roxithromycin Atid cannot be excluded, administration of

Roxithromycin Atid to patients taking ergot alkaloids is contraindicated.

Disopyramide. An in vitro study has shown that Roxithromycin Atid can displace

protein bound disopyramide; such an effect in vivo could result in increased

serum levels of disopyramide. Consequently, ECG and, if possible,

disopyramide serum levels should be monitored.

Terfenadine. Some macrolide antibiotics (e.g. erythromycin) may increase

serum levels of terfenadine. This can result in severe cardiovascular adverse

events, including QT prolongation, torsades de pointes and other ventricular

arrhythmias. Such a reaction has not been documented with Roxithromycin Atid,

which has a much lower affinity for cytochrome P450 than erythromycin.

However, in the absence of a systematic interaction study, concomitant

administration of Roxithromycin Atid and terfenadine is not recommended.

Astemizole, cisapride, pimozide. Other drugs, such as astemizole, cisapride

or pimozide, which are metabolised by the hepatic isozyme CYP3A4, have

been associated with QT interval prolongation and/or cardiac arrhythmias

(typically torsades de pointes) as a result of an increase in their serum level

subsequent to interaction with significant inhibitors of this isozyme, including

some macrolide antibacterials. Although Roxithromycin Atid has no or limited ability

to complex CYP3A4 and hence to inhibit the metabolism of other drugs

processed by this isozyme, a potential for clinical interaction of Roxithromycin Atid

with the above mentioned drugs cannot be either ascertained or ruled out in

confidence. Thus, concomitant administration of Roxithromycin Atid and such drugs

is not recommended.

Warfarin. While no interaction was observed in volunteer studies,

Roxithromycin Atid appears to interact with warfarin. Increases in prothrombin time

(international normalised ratio (INR)) have been reported in patients treated

concomitantly with Roxithromycin Atid and warfarin or the related vitamin K

antagonist phenprocoumon, and severe bleeding episodes have occurred as

a consequence.

Digoxin and other cardiac glycosides. A study in healthy volunteers has

shown that Roxithromycin Atid may increase the absorption of digoxin. This effect,

common to other macrolides, may very rarely result in cardiac glycoside

toxicity. This may be manifested by symptoms such as nausea, vomiting,

diarrhoea, headache or dizziness. Cardiac glycoside toxicity may also elicit

heart conduction and/or rhythm disorders. Consequently, in patients treated

with Roxithromycin Atid and digoxin or another cardiac glycoside, ECG and, if

possible, the serum level of the cardiac glycoside should be monitored. This is

mandatory if symptoms suggesting cardiac glycoside overdosage have


Midazolam. Roxithromycin Atid, like other macrolides, may increase the area

under the midazolam concentration-time curve and the midazolam half-life.

Thus, the effects of midazolam may be enhanced and prolonged in patients treated with Roxithromycin Atid. There is no conclusive evidence for an interaction

between Roxithromycin Atid and triazolam.

Cyclosporin. A slight increase in plasma concentrations of cyclosporin A has

been observed. This does not generally necessitate altering the usual dosage.



  1. FDA/SPL Indexing Data. "21KOF230FA: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". (accessed September 17, 2018).
  2. MeSH. "Anti-Bacterial Agents". (accessed September 17, 2018).
  3. European Chemicals Agency - ECHA. "(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". (accessed September 17, 2018).


The results of a survey conducted on for Roxithromycin Atid are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Roxithromycin Atid. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet

Consumer reported doses

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 18 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2019 All Rights Reserved